Web25. mar 2024. · Some data indicate that patients with EGFR-mutated NSCLC may gain less benefit from durvalumab consolidation while experiencing a greater risk of immune-related adverse events (AEs). ... In patients with oncogenic drivers, median PFS was not correlated with PD-L1 expression. OS rate in patients with genomic drivers at 18 months …
Rare molecular subtypes of lung cancer Nature Reviews Clinical …
WebNonsmall cell lung cancer (NSCLC) is increasingly being treated with targeted therapies. Epidermal growth factor receptor (EGFR) has been extensively studied in NSCLC as an … Web13. apr 2024. · Although chemotherapy plus PD-1 blockade (chemo+anti-PD-1) has become the standard first-line therapy for advanced esophageal squamous cell carcinoma … hutch inc
Targeting oncogenic drivers in lung cancer: Recent progress, …
Web21. jan 2024. · *December 2024* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer (NSCLC), redirecting attention toward advances in biomarker testing methodologies. Web01. dec 2024. · Rearranged during transfection (RET) is an oncogenic driver activated by either RET fusions or mutations.RET fusions occur predominantly in 2% of lung cancers and 10–20% of thyroid cancers and in low frequency in an increasing number of diverse cancers.. Various nonselective multikinase inhibitors with ancillary RET inhibitory activity … Web14. apr 2024. · A variety of oncogenic drivers have been identified in non–small cell lung cancer (NSCLC), and molecular targeted therapy has greatly improved the clinical outcomes of patients with oncogenic drivers . Plasma cell-free DNA (cfDNA) sequencing has been developed as a less invasive method than conventional tissue genotyping for detecting … hutchin bar mckinney